ImmunoCellular buys into CAR-Ts for cancer; Epirus lands a Chinese biosimilar deal;

@FierceBiotech: VentiRx banks $50M as it ramps up immuno-oncology research efforts in Seattle. Report | Follow @FierceBiotech

@JohnCFierce: Adaptimmune gathers $104M to fuel hot immuno-oncology tech race - TCRs/CAR-T. More | Follow @JohnCFierce

@DamianFierce: Here's the official Kadmon release on the Waksal swap, replete with semi-acknowledgement of IPO plot. Release | Follow @DamianFierce

@EmilyMFierce: This  on  misses the mark in so many ways and lacks a basic understanding of drug development. Article | Follow @EmilyMFierce

> ImmunoCellular ($IMUC) is diving into the field of CAR-T immunotherapies for cancer, licensing technology from the California Institute of Technology to develop modified T cells for future therapies. More

> Inovio Pharmaceuticals ($INO) is planning to get its Ebola vaccine into clinical trials in the first half of next year. Story

> Boston biotech Epirus has struck a deal with China's Livzon Mabpharm under which the two will collaborate on up to 5 biosimilars, starting with a take on the blockbuster Remicade. News

> Blaze Bioscience has kicked off a Phase Ib study for its lead brain cancer candidate. Item (PDF)

Medical Device News

@FierceMedDev: NIH launches study of 'exceptional responders' to cancer therapies. Article | Follow @FierceMedDev

@MichaelGFierce: Purdue team recreates tumor microenvironment to study cancer nanomed delivery. FierceDrugDelivery story | Follow @MichaelGFierce

@VarunSaxena2: Titan Pharma trial of implant for addicts on track. FierceDrugDelivery story | Follow @VarunSaxena2

@EmilyWFierce: 3-D printed blood vessels? Check. On to the 3-D printed kidneys, say researchers at Harvard. More from MIT Technology Review | Follow @EmilyWFierce

> At least 23 digital health apps clear FDA this year. Item

> Court rules that Boston Scientific owes inventor of pacemaker $309M. Report

Pharma News

@FiercePharma: ICYMI yesterday: Overseas limits on J&J's Olysio use might signal trouble back home. Item | More | Follow @FiercePharma

@EricPFierce: Mylan proposes plan to avoid nitroglycerin shortage in Canada. ICYMI from FiercePharmaManufacturing | Follow @EricPFierce

> Pfizer preps its case for FDA pulling Chantix's black-box warning. Article

> Hail GSK's chairman-to-be Phillip Hampton: It's a tough job ahead. Item

> Hey, Big Pharma: When the feds swoop in, be nice. It worked for Shire. More

Vaccines News

> Inovio joins Ebola fight while WHO says a vaccine could be ready by year's end. Story

> CureVac inks lung cancer vaccine deal with Boehringer for up to $600M. Report

> U.K. panel under pressure to extend use of Merck's Gardasil to boys. Article

> Pharmacies continue push to lower barriers to seasonal flu vaccination. Report

> Accidental poliovirus dump adds to GSK's production woes. More

Pharma Manufacturing News

> IGI jumps into sterile injectable biz with $9.5M deal with AstraZeneca. More

> Report: 'Green' manufacturing needed to save money as well as the environment. Item

> Sanofi expands production at Merial plant in Brazil. More

> Alkermes manufacturing technology key to Acorda buyout of Civitas. Article

> Impax settles securities suit tied to its manufacturing issues. Story

Suggested Articles

The $3 billion funding boost includes an additional $350 million for targeted Alzheimer’s research.

Less than two years after taking the reins from founding chief Rusty Williams, Five Prime Therapeutics CEO Aron Knickerbocker is exiting the company.

The RV144 HIV vaccine regimen containing clades B and E inserts produced strong immune responses in South Africa, where clade C dominates.